Botox injections

Categoria: Aesthetics Archive EN Cosmetic Surgery Food and Drug Administration (FDA) Medicines
Tag: #bacteria #Cosmetic Surgery #face #injections
Condividi:

Botox is the best-known trade name of the pharmacological preparation that uses botulinum toxin, a neurotoxic protein produced by the bacterium Clostridium botulinum, as an active ingredient, for face lifting . Botulinum toxin is a double-chain polypeptide, with one 100 kDa chain disulfide-linked to another 50 kDa chain. The light chain is a protease enzyme that attacks one of the proteins (SNAP-25, syntaxin or synaptobrevin) of the neuromuscular junction, preventing the release of acetylcholine from the vesicles. By inhibiting the release of this neurotransmitter, the toxin interferes with nerve impulses and causes flaccid muscle paralysis characteristic of botulism and in contrast to the spastic paralysis seen in tetanus. In recent days, thanks to an article in the London newspaper The Sun, the other side of the coin has been brought to light, namely the dangers of Botox injections which in some cases can even lead to death. In England alone in the past year there would have been at least sixteen victims, including four minors. Doctors hypothesize that the cause of death is the fact that the botulinum toxin introduced into the body can expand into nearby tissues such as the esophagus, paralyzing or in any case severely limiting the organ's functions. The percentage of deceased patients resulting from the 55,000 injections is not high (less than one person in a thousand), but as requested by some of the consumer associations, it is necessary -rightly- to include all the adverse effects that can be expected in the contraindications to reach out to. In 1937 Alan B. Scott, an ophthalmologist at the Smith-Kettlewell Institute, used botulinum toxin A (BTX-A) in experiments on monkeys, and in 1980 he used BTX-A for the first time in humans for the treatment of strabismus. BTX-A was approved in 1989 by the Food and Drug Administration for the treatment of strabismus, blepharospasm, and hemifacial spasm in patients older than 12 years. In 2002, it received approval for use in aesthetic medicine for the temporary improvement of expression lines between the eyebrows (glabellar lines) through small skin injections that have a muscle-relaxing effect for up to 4 5 months. [more info ]

Publicato: 2008-01-28Da: Bio Blog

Potrebbe interessarti